We studied changes in the bone tissue in patients with diffuse large B-cell lymphoma at the onset of the disease (N=41; before chemotherapy) and 5-16 years after the end of treatment (N=47). Osteodensitometry, biochemical markers of osteoporosis in the blood and urine, and gene expression in multipotent mesenchymal stromal cells were analyzed. In multipotent mesenchymal stromal cells of all patients, the expression of genes associated with bone and cartilage differentiation (FGF2, FGFR1, FGFR2, BGLAP, SPP1, TGFB1, and SOX9) was changed. In primary patients, the ratio of deoxypyridinoline/creatinine in the urine and blood level of β-cross-laps were increased, while plasma concentration of vitamin D was reduced, which indicates activation of bone resorption. No differences between the groups were revealed by osteodensitometry. No direct relationship between changes in gene expression in multipotent mesenchymal stromal cells and osteoporosis markers was found. The presence of a tumor in the body affects the bone marrow stroma, but achievement of remission and compensatory mechanisms provide age-appropriate condition of the bone tissue.

中文翻译：

---

未累及骨髓的弥漫性大B细胞淋巴瘤患者骨组织状况分析

我们研究了弥漫性大 B 细胞淋巴瘤患者在疾病发作时（N=41；化疗前）和治疗结束后 5-16 年（N=47）骨组织的变化。分析了骨密度测定法、血液和尿液中骨质疏松症的生化标志物以及多能间充质基质细胞中的基因表达。在所有患者的多能间充质基质细胞中，与骨和软骨分化相关的基因（FGF2、FGFR1、FGFR2、BGLAP、SPP1、TGFB1和SOX9）的表达发生了变化。在原发患者中，尿中脱氧吡啶啉/肌酐比值和血β-cross-laps水平升高，而血浆维生素D浓度降低，表明骨吸收激活。骨密度测定法未显示组间差异。未发现多能间充质基质细胞中基因表达变化与骨质疏松标志物之间的直接关系。体内肿瘤的存在会影响骨髓基质，但缓解和代偿机制的实现提供了适合年龄的骨组织状况。